Changing the Status Quo: Four Landmark Studies and their Implication for Melanoma Treatment
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 13 November 2017 In News, Science
The crown jewel of the Melanoma Research Alliance has always been—and will always be—good science. Through science, we not only gain a better understanding of melanoma, but the ability to translate that understanding into better treatments, which in turn lead to a better quality of life for people with melanoma. At MRA, solid scientific leadership is at the forefront of everything we do. That’s why the MRA Board of Directors was thrilled to hear a presentation by fellow Board member and world-class researcher, Dr. Suzanne Topalian, on four landmark studies and their implications for melanoma treatment.
A Mother’s Perspective: New Options for Pediatric Melanoma
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 6 September 2017 In Melanoma Stories, News, Treatment
When Cheryl Trocke’s nine-year old son Graham was diagnosed with melanoma four years ago, she quickly learned that when it comes to kids, there were no great treatment options and that care can vary greatly based on where your child is treated. After surgically removing the primary tumor, Graham’s doctors suggested a treatment plan of ‘wait and see.’
Doubling Down: Brandon Barniea Bets Big on Combination Therapy
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 6 September 2017 In Melanoma Stories, Treatment
Brandon Barniea didn’t believe he needed to visit doctors. The athletic 35-year-old had always been healthy – even when his wife and two kids were sick at home with the flu, he would miraculously avoid falling ill. So, when he found what felt like “beads” in his neck, reality came crashing in; following a biopsy, he was diagnosed first with stage III melanoma in August 2015 and later that year it progressed to stage IV.
Melanoma Treatments: Breakthroughs for Multiple Cancers — for Real and Right Now
While 2014 and 2015 offered a whirlwind of good news related to new melanoma treatments from immune to targeted therapy, since then, it’s been a bit quieter in melanoma. Although there has been exceptional news in regard to other cancers. Why is that, and what are the latest breakthroughs?
Melanoma Research Alliance and the American Cancer Society Forge Research Partnership to Maximize Immunotherapy Benefit to Patients
The Melanoma Research Alliance (MRA) and the American Cancer Society (ACS) are partnering to fund much-needed research aimed at decreasing rare, but serious, side effects associated with checkpoint inhibitors in hopes of increasing further cancer immunotherapy benefit to patients.
What Gut Bacteria Tell Us About Treating Melanoma and Other Cancers
Despite success in the use of immunotherapy to treat cancer by harnessing the body’s immune system to fight it, a major difficulty continues to be the range of responses to treatment among patients. It’s why researchers are exploring why some cancer patients exhibit astounding results with little side effects while others receive no benefits to the treatment and/or experience severe side effects.
The Power of Combination Therapies: One Patient’s Road to Remission
Metastatic melanoma can be a devastating diagnosis to receive. Just hearing the word cancer for most is terrifying. While the fear is understandable, today new targeted therapies and immunotherapies are delivering new hope for many.